Factor XIa Inhibitor Design via Local Quality and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thrombosis, embolism, hypercoagulability, and fibrotic changes are inadequate, as existing inhibitors have limitations in potency, efficacy, and pharmacokinetic profiles, and there is a need for selective inhibitors of Factor XIa and plasma kallikrein to address these conditions effectively.
Innovation Solution
Development of compounds of Formula I, which are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein, designed to treat various disease states by inhibiting Factor XIa or plasma kallikrein, including thrombosis, embolism, hypercoagulability, and fibrotic changes, with improved pharmacokinetic profiles and potency compared to existing compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors are used to treat thrombosis and embolism, then treatment is provided, but potency and efficacy are insufficient
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of Factor XIa inhibitors through systematic variation of molecular components (aromatic rings, linkers, terminal groups) to achieve optimal binding affinity and selectivity. This structural optimization resolves the contradiction by enhancing inhibitor potency while maintaining selectivity for Factor XIa over other coagulation factors.
Solution Approach 2:
The patent applies local quality by designing specific functional regions within the inhibitor molecule that interact with distinct pockets of the Factor XIa active site. Different portions of the inhibitor are optimized to interact with specific residues in the substrate binding region, thereby enhancing binding affinity and selectivity without affecting other coagulation factors.
2Reliability
If existing inhibitors are used, then treatment is provided, but pharmacokinetic profiles are inadequate
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular properties such as lipophilicity, molecular weight, and hydrogen bonding capacity. These changes improve absorption, distribution, metabolism, and excretion characteristics of the inhibitors, enabling effective plasma concentration maintenance with reduced dosing frequency and enhanced safety profile.
3Reliability
If selective inhibitors of Factor XIa and plasma kallikrein are developed, then potency and efficacy are improved, but device complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules: an aromatic ring system for hydrophobic interactions, a linker region for structural flexibility, and a terminal group for specific hydrogen bonding. This modular design enables systematic optimization of potency while maintaining synthetic accessibility and structural clarity.
Data Source
AI summary
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.